Claus‐Henning Köhne

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

Gunnar Folprecht, Thomas Gruenberger, Wolf O. Bechstein et al. · The Lancet Oncology · 2009 · 960 citations

Medicine, Oncology, Chemotherapy +16

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

Carsten Bokemeyer, Eric Van Cutsem, Philippe Rougier et al. · European Journal of Cancer · 2012 · 593 citations

Medicine, Oncology, Pharmacology +12

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

Richard Herrmann, G. Bodoky, Thomas Ruhstaller et al. · Journal of Clinical Oncology · 2007 · 591 citations

Medicine, Oncology, Pharmacology +15

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

Sabine Käyser, Konstanze Döhner, Jürgen Krauter et al. · Blood · 2010 · 485 citations

Medicine, Hematology, Oncology +11